A monoclonal antibody is an immunoglobulin produced by a single clone of plasma cells and therefore identical in sequence and antigen specificity. These antibodies bind to a single epitope on an antigen, unlike polyclonal antibodies that recognize multiple epitopes.
Production and Applications
Monoclonal antibodies are generated using techniques that fuse a B cell producing a desired antibody with an immortal myeloma cell to create a hybridoma capable of secreting large amounts of a single antibody. Modern methods also employ recombinant DNA technology to engineer humanized or fully human antibodies to reduce immunogenicity. The resulting proteins maintain a uniform structure because they originate from one parent cell line. Their specificity makes them valuable for precisely detecting antigens in research, diagnostics, and clinical settings. In diagnostic assays such as enzyme-linked immunosorbent assays and rapid tests, monoclonal antibodies bind to a target pathogen or biomarker, enabling highly specific detection. Therapeutically, they are used to target cell surface proteins in cancers, inflammatory diseases, and infections. Chimeric or humanized versions of these antibodies can deliver cytotoxic agents directly to malignant cells or block receptor signaling pathways. Variations include conjugated antibodies linked to drugs or radioisotopes and bispecific antibodies that bind two different antigens. Production requires careful screening of hybridoma clones and large-scale culture, followed by purification to remove contaminants. Limitations include the potential for immune reactions, antigen escape, and the high cost of production. Ongoing advances in expression systems and protein engineering continue to improve safety and accessibility and expand the range of targets.
Notable Therapeutic Examples
Rituximab targets the CD20 antigen on B cells and is used to treat non‑Hodgkin lymphoma and some autoimmune disorders. Trastuzumab binds the HER2 receptor, slowing growth of HER2‑positive breast and gastric cancers. Infliximab, adalimumab and similar agents neutralize tumour necrosis factor‑alpha, providing relief in rheumatoid arthritis and inflammatory bowel disease. Omalizumab targets IgE to reduce allergic asthma severity. Muromonab‑CD3, the first monoclonal antibody approved for clinical use, was used to prevent transplant rejection. These drugs illustrate how selecting an antigen and engineering a matching antibody can lead to targeted treatments with fewer off‑target effects than conventional chemotherapy. Monoclonal antibodies have transformed laboratory diagnostics and targeted therapies by offering high specificity and reproducible performance. Their development showcases how cell fusion and protein engineering yield uniform molecules that precisely modulate biological processes. As technology advances, these molecules will continue to broaden the toolkit for treating disease. Related Terms: Polyclonal Antibody, Epitope, Antigen, Hybridoma, Immunotherapy